Blogger's Note: this Editorial requires a subscription ($$$)
Editorial
Tumor Heterogeneity and Personalized Medicine
This article has no abstract; the first 100 words appear below.
"In
the past 10 years, the number of tools available to treat cancer has
increased, as has our understanding of what makes some cancers tick. The
standard old-time cancer treatments were largely predicated on
attacking DNA, an approach fueled by the belief that tumor cells divide
more rapidly than normal cells. However, with the notable exception of
Burkitt's lymphoma, only a small percentage of tumor cells in a patient
are dividing at any given time. As we have learned more about DNA repair
mechanisms and epigenetic alterations in cancers, DNA remains a viable
target for new cancer therapies, but DNA . . ."